UY26844A1 - Nuevos derivados de la pirrolidona - Google Patents

Nuevos derivados de la pirrolidona

Info

Publication number
UY26844A1
UY26844A1 UY26844A UY26844A UY26844A1 UY 26844 A1 UY26844 A1 UY 26844A1 UY 26844 A UY26844 A UY 26844A UY 26844 A UY26844 A UY 26844A UY 26844 A1 UY26844 A1 UY 26844A1
Authority
UY
Uruguay
Prior art keywords
pirrolidona
new derivatives
compounds
metalloproteases
inhibitors
Prior art date
Application number
UY26844A
Other languages
English (en)
Inventor
Eric Argirios Kitas
Henrietta Dehmlow
Johannes Aebi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26844A1 publication Critical patent/UY26844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a los compuestos de fórmula I en donde R1, R2, R3, R4, R5 y X son como se ha definido en la descripción y las reivindicaciones y los ésteres y/o las sales farmacéuticamente aceptables de los mismos. Los compuestos son de utilidad como inhibidores de las metaloproteasas, por ejemplo zinc proteasas, en particular zinc hidrolasas, y los cuales son efectivos en el tratamiento de estados de enfermedad, asociados con la vaso constricción de incidentes crecientes.
UY26844A 2000-07-19 2001-07-17 Nuevos derivados de la pirrolidona UY26844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00114948 2000-07-19

Publications (1)

Publication Number Publication Date
UY26844A1 true UY26844A1 (es) 2002-01-31

Family

ID=8169225

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26844A UY26844A1 (es) 2000-07-19 2001-07-17 Nuevos derivados de la pirrolidona

Country Status (18)

Country Link
US (1) US6444829B1 (es)
EP (1) EP1317428B1 (es)
JP (1) JP2004504298A (es)
KR (1) KR100580056B1 (es)
CN (1) CN1318402C (es)
AR (1) AR033543A1 (es)
AT (1) ATE323673T1 (es)
AU (1) AU2001276396A1 (es)
BR (1) BR0112543A (es)
CA (1) CA2415665A1 (es)
DE (1) DE60118941T2 (es)
ES (1) ES2261443T3 (es)
MX (1) MXPA03000363A (es)
PA (1) PA8522401A1 (es)
PE (1) PE20020339A1 (es)
UY (1) UY26844A1 (es)
WO (1) WO2002006224A1 (es)
ZA (1) ZA200300172B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
CN103145572A (zh) * 2013-03-20 2013-06-12 康化（上海）新药研发有限公司 天然产物氯化γ-正缬氨酸盐酸盐的不对称合成方法
CN105712910B (zh) * 2016-03-08 2017-06-06 北京化工大学 （n‑芳基亚磺酰基）磺酰肼及其制备方法
JPWO2021029158A1 (es) * 2019-08-09 2021-02-18
CN113030292A (zh) * 2021-01-29 2021-06-25 京博农化科技有限公司 一种对三氟甲氧基苯胺基甲酰肼含量的分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493333A (en) * 1893-03-14 Air-heating furnace
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process
DK0927161T3 (da) * 1996-08-28 2003-02-17 Procter & Gamble Substitueret cyklisk amin-metalloproteaseinhibitorer

Also Published As

Publication number Publication date
AR033543A1 (es) 2003-12-26
US6444829B1 (en) 2002-09-03
CN1318402C (zh) 2007-05-30
EP1317428A1 (en) 2003-06-11
PE20020339A1 (es) 2002-04-23
ATE323673T1 (de) 2006-05-15
MXPA03000363A (es) 2003-05-27
BR0112543A (pt) 2003-07-01
CA2415665A1 (en) 2002-01-24
AU2001276396A1 (en) 2002-01-30
CN1443163A (zh) 2003-09-17
ZA200300172B (en) 2004-04-07
DE60118941T2 (de) 2006-12-21
US20020040048A1 (en) 2002-04-04
JP2004504298A (ja) 2004-02-12
WO2002006224A1 (en) 2002-01-24
PA8522401A1 (es) 2002-09-30
KR20030024797A (ko) 2003-03-26
DE60118941D1 (de) 2006-05-24
EP1317428B1 (en) 2006-04-19
KR100580056B1 (ko) 2006-05-12
ES2261443T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
ECSP055696A (es) Acetil 2-hidroxi-1, 3-diaminoalcanos
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
CR8147A (es) Derivados de pirido 2, 1a-isoquinolina, como inhibidores de dpp-iv
ECSP045100A (es) N,N'-substituted-1,3-Diamino-2-Hydroxypropane Derivatives
UY26872A1 (es) Derivados de la 4- fenil piridina
ES2213732T3 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
UY26721A1 (es) Nuevos derivados de la fenilglicina
PA8478501A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
AR039385A1 (es) Derivados de tioxantina como inhibidores de la mieloperoxidasa
PA8485101A1 (es) Nuevos antibioticos macrolidos.
UY26847A1 (es) Derivados de la pirrolidina
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
GT200300284A (es) Derivados de 3h-quinazolin-4-ona
AR021714A1 (es) Nuevos compuestos biciclicos.
PA8589801A1 (es) Aminoalcoxiindoles
UY26844A1 (es) Nuevos derivados de la pirrolidona
PA8581201A1 (es) Nuevos derivados de tiazol
UY26846A1 (es) Derivados de la pirrolidina
GT200300066A (es) Derivados de ciclopenteno
AR039937A1 (es) Derivados de azetidina como inhibidores de tripsina proteasas
UY26845A1 (es) Derivados de la pirimidina
UY27448A1 (es) Ésteres de análogos de 3-desoxi-vitamina d3

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140725